Clofarabine - Sanofi Genzyme

Drug Profile

Clofarabine - Sanofi Genzyme

Alternative Names: CAFdA; Cl-F-ara-A; Clofaribine; Clolar; Evoltra; GZ393590; JC0707; SAR 393590

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Southern Research Institute
  • Developer Bioenvision; Dana-Farber Cancer Institute; Erasmus MC; Genzyme Corporation; Genzyme Oncology; Massachusetts General Hospital; Oncology Specialists S.C.; Sanofi Genzyme; Sanofi Oncology; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; University Hospital Southampton NHS Foundation Trust; University of Michigan Comprehensive Cancer Center; University of Utah; Yale University
  • Class Antineoplastics; Furans; Purine nucleosides; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Histiocytosis
  • Phase I/II Haematological malignancies
  • Preregistration Submission Withdrawal Acute myeloid leukaemia
  • Discontinued B cell lymphoma; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Psoriasis; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 13 Feb 2018 Genzyme terminates a phase I trial due to lack of accrual in Precursor cell lymphoblastic leukaemia lymphoma, Acute myeloid leukaemia and Myelodysplastic syndrome (Second-line therapy or greater, Combination therapy, In infants, In children, In adolescents, In adults) in USA and Canada (IV) (NCT00852709)
  • 25 May 2017 Genzyme terminates a phase I/II trial for Myelodysplastic syndromes and Chronic myelomonocytic leukaemia (Second-line therapy or greater) as data analysis revealed sufficient data for safety and efficacy in USA (PO) (NCT00708721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top